Endo wins over Auxilium, QLT dropped

Endo is to acquire Auxilium Pharmaceuticals in a deal worth $2.6bn, just weeks after Auxilium's board unanimously rejected a previous $2.2bn offer (scripintelligence.com, 23 September 2014).

Endo is to acquire Auxilium Pharmaceuticals in a deal worth $2.6bn, just weeks after Auxilium's board unanimously rejected a previous $2.2bn offer (scripintelligence.com, 23 September 2014).

Under the agreement, Endo will acquire all of the outstanding shares of common stock of Auxilium for $33.25 per share...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Immunological

More from Therapeutic Category